CPC A61K 35/17 (2013.01) [C07K 14/7155 (2013.01); C07K 2317/24 (2013.01); C07K 2317/565 (2013.01); C07K 2317/622 (2013.01); C07K 2317/73 (2013.01); C07K 2317/76 (2013.01); C07K 2319/03 (2013.01)] | 19 Claims |
1. A method for reducing the risk of cytokine release syndrome in a patient receiving an immunotherapy, the method comprising administering to the patient T cells comprising a heterologous nucleic acid molecule encoding an anti-IL-6Rα single chain antibody variable fragment (scFv) comprising a heavy chain variable region comprising CDR1 (SEQ ID NO:5), CDR2 (SEQ ID NO:6), and CDR3 (SEQ ID NO:7) attached by a heterologous linker to a light chain variable region comprising CDR4 (SEQ ID NO:8), CDR5 (SEQ ID NO:9), and CDR6 (SEQ ID NO:10), wherein the heterologous nucleic acid is expressed in the T cells.
|